[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 5480
86. Guvendag Guven ES, Okur H, Beksac MS: Placental fas/fas ligand expression in early pregnancy losses. Am J Reprod Immunol; 2008 Jul;60(1):1-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Placental fas/fas ligand expression in early pregnancy losses.
  • PROBLEM: The aim of this study was to compare the expression levels of Fas and Fas ligand (FasL) in first-trimester placentas obtained from spontaneous abortions in patients with antiphospholipid antibody syndrome (APS) or factor V (FV) Leiden mutation, compared with values in placentas from induced abortions in patients negative for these conditions.
  • [MeSH-major] Abortion, Spontaneous / metabolism. Antigens, CD95 / biosynthesis. Fas Ligand Protein / biosynthesis. Placenta / metabolism
  • [MeSH-minor] Antiphospholipid Syndrome / complications. Factor V / metabolism. Female. Flow Cytometry. Fluorescent Antibody Technique. Humans. Immune Tolerance / physiology. Pregnancy. Pregnancy Trimester, First

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Miscarriage.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18422813.001).
  • [ISSN] 1046-7408
  • [Journal-full-title] American journal of reproductive immunology (New York, N.Y. : 1989)
  • [ISO-abbreviation] Am. J. Reprod. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Fas Ligand Protein; 0 / factor V Leiden; 9001-24-5 / Factor V
  •  go-up   go-down


87. Bozic B, Cucnik S, Kveder T, Rozman B: Avidity of anti-beta-2-glycoprotein I antibodies. Autoimmun Rev; 2005 Jun;4(5):303-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Avidity of anti-beta-2-glycoprotein I antibodies.
  • Since affinity refers to monovalent binding of antibodies to a monovalent epitope, the majority of data on the binding of anti-beta2-glycoprotein I antibodies (anti-beta2-GPI) characterized their avidity rather than affinity.
  • Anti-beta2-GPI were generally believed to be of low avidity, but heterogeneous avidity of patients' IgG anti-beta2-GPI has been demonstrated.
  • High avidity anti-beta2-GPI monoclonals were reported to possess higher pathogenicity than low avidity anti-beta2-GPI.
  • Polyclonal high avidity anti-beta2-GPI were found to be more common in patients with antiphospholipid syndrome (APS) and associated with thrombosis.
  • Some conformational changes of beta2-GPI are required for the binding of polyclonal anti-beta2-GPI to the antigen: neither high density of the antigen nor high avidity of the anti-beta2-GPI alone is sufficient for the recognition.
  • Avidity of anti-beta2-GPI should be considered in any attempt of inter-laboratory standardisation and/or evaluation of anti-beta2-GPI enzyme-linked immunosorbent assay (ELISA).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15990078.001).
  • [ISSN] 1568-9972
  • [Journal-full-title] Autoimmunity reviews
  • [ISO-abbreviation] Autoimmun Rev
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Glycoproteins; 0 / beta 2-Glycoprotein I
  • [Number-of-references] 40
  •  go-up   go-down


88. Yamasaki Y, Narain S, Yoshida H, Hernandez L, Barker T, Hahn PC, Sobel ES, Segal MS, Richards HB, Chan EK, Reeves WH, Satoh M: Autoantibodies to RNA helicase A: a new serologic marker of early lupus. Arthritis Rheum; 2007 Feb;56(2):596-604
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the clinical and immunologic significance of autoantibodies to RNA helicase A (RHA) in patients with systemic rheumatic diseases.
  • RESULTS: Anti-RHA was observed in 17 (6.2%) of 276 patients with systemic lupus erythematosus (SLE), 2 patients with antiphospholipid antibodies, and 3 other patients, but anti-RHA was not observed in any patient with polymyositis/dermatomyositis, systemic sclerosis, rheumatoid arthritis, or Sjögren's syndrome.
  • Anti-RHA was present in only 2.9% of African American patients, compared with 6.0% of white patients and 12-25% of patients of other races; this was in striking contrast to the frequency of anti-Sm in African American patients (27.2%).
  • Among patients with SLE, anti-RHA was common in young patients (26% of those whose initial visit was at an age younger than 20 years versus 3-4% of those who were initially seen at ages 20-49 years) and at an early stage of disease (23% of those whose first clinic visit was within 1 year of disease onset versus 2-8% of those whose first visit was at least 1 year after disease onset).
  • In 9 of 11 patients, levels of anti-RHA decreased to <10% of the initial value within 9-37 months, while levels of coexisting anti-Ro or anti-Su remained the same.
  • New specificities developed in 2 patients (anti-nuclear RNP and anti-Sm, and anti-ribosomal P, respectively).
  • These data suggest that the level of anti-RHA diminishes over time, and that anti-RHA is regulated via a mechanism different from that for other lupus-related autoantibodies.
  • CONCLUSION: Anti-RHA is a new serologic marker for SLE.
  • It is produced mainly in young non-African Americans at an early stage of their disease.
  • Anti-RHA has a unique tendency to diminish over time.
  • The production of anti-RHA may depend on a process restricted to early SLE, or it may be highly sensitive to treatment.
  • [MeSH-major] Autoantibodies / blood. DEAD-box RNA Helicases / immunology. Lupus Erythematosus, Systemic / diagnosis. Lupus Erythematosus, Systemic / immunology. Neoplasm Proteins / immunology

  • Genetic Alliance. consumer health - Lupus.
  • MedlinePlus Health Information. consumer health - Lupus.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17265494.001).
  • [ISSN] 0004-3591
  • [Journal-full-title] Arthritis and rheumatism
  • [ISO-abbreviation] Arthritis Rheum.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI-39645; United States / NIAID NIH HHS / AI / AI-47859; United States / NIAMS NIH HHS / AR / AR-050661; United States / NIAMS NIH HHS / AR / AR-40391; United States / NCRR NIH HHS / RR / M01-RR-00082
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Autoantigens; 0 / Neoplasm Proteins; 0 / Ribonucleoproteins, Small Nuclear; 0 / snRNP Core Proteins; EC 3.6.1.- / DHX9 protein, human; EC 3.6.4.13 / DEAD-box RNA Helicases
  •  go-up   go-down


89. Surga N, Makdassi R, Choukroun G, Vandwalle J, Petit J, Saint F: [Adrenal hemorrhage acutised by adrenocorticotropin hormone]. Prog Urol; 2010 Jun;20(6):425-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We associated a clinical, endocrine and radiologic staging to treat those patients.
  • Two patients suffered of the condition of the antiphospholipid syndrome.
  • The clinical attitude has thus to be defined clearly.
  • The patient must be under close clinical evaluation.
  • Antiphospholipid syndrome must also be excluded.

  • MedlinePlus Health Information. consumer health - Adrenal Gland Disorders.
  • MedlinePlus Health Information. consumer health - Bleeding.
  • MedlinePlus Health Information. consumer health - Hormones.
  • Hazardous Substances Data Bank. Cosyntropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20538206.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Hormones; 16960-16-0 / Cosyntropin; 53468-06-7 / adrenocorticotropin zinc
  •  go-up   go-down


90. Binet F, Girard D: Novel human neutrophil agonistic properties of arsenic trioxide: involvement of p38 mitogen-activated protein kinase and/or c-jun NH2-terminal MAPK but not extracellular signal-regulated kinases-1/2. J Leukoc Biol; 2008 Dec;84(6):1613-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Arsenic trioxide (ATO) is known for treating acute promyelocytic leukemia and for inducing apoptosis and mitogen-activated protein kinases (MAPKs) in promyelocytes and cancer cells.

  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18728151.001).
  • [ISSN] 0741-5400
  • [Journal-full-title] Journal of leukocyte biology
  • [ISO-abbreviation] J. Leukoc. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oxides; 0 / Reactive Oxygen Species; BBX060AN9V / Hydrogen Peroxide; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; EC 3.4.24.- / Gelatinases; S7V92P67HO / arsenic trioxide; SY7Q814VUP / Calcium
  •  go-up   go-down


91. Gigante A, Gasperini ML, Cianci R, Barbano B, Giannakakis K, Di Donato D, Fuiano G, Amoroso A: Antiphospholipid antibodies and renal involvement. Am J Nephrol; 2009;30(5):405-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antiphospholipid antibodies and renal involvement.
  • Antiphospholipid antibodies are a heterogeneous group of autoantibodies associated with the hypercoagulable state affecting all vascular districts with thrombosis named antiphospholipid syndrome (APS).
  • APS is an autoimmune disease with multifactorial etiology that includes cellular, molecular, genetic and pathogenic mechanisms.
  • The APS clinical features are a combination of arterial and/or venous thrombosis, hematological events, recurrent fetal losses, neurological disorders and intra-abdominal manifestations.
  • Clinical features include hypertension, renal artery stenosis, thrombotic microangiopathy and other histological manifestations of the nephropathy (APSN), venous renal thrombosis, APSN in the course of systemic lupus erythematosus and renal failure.
  • APSN is an independent risk factor that should be included in the classification criteria for definite APS with characteristic clinical and histological features.
  • [MeSH-major] Antibodies, Antiphospholipid / blood. Antiphospholipid Syndrome / immunology. Kidney / immunology. Kidney Diseases / immunology

  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19713697.001).
  • [ISSN] 1421-9670
  • [Journal-full-title] American journal of nephrology
  • [ISO-abbreviation] Am. J. Nephrol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibodies, Antiphospholipid
  • [Number-of-references] 40
  •  go-up   go-down


92. O'Neil KM: High-intensity warfarin versus conventional antithrombotic therapy to prevent thrombosis in antiphospholipid syndrome. Curr Rheumatol Rep; 2007 Jun;9(3):188-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-intensity warfarin versus conventional antithrombotic therapy to prevent thrombosis in antiphospholipid syndrome.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Lupus. 2005;14(2):120-8 [15751816.001]
  • (PMID = 17531170.001).
  • [ISSN] 1523-3774
  • [Journal-full-title] Current rheumatology reports
  • [ISO-abbreviation] Curr Rheumatol Rep
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Bhowmik D, Dadhwal V, Dinda AK, Handa R, Dash SC: Steroid-responsive focal segmental glomerulosclerosis in primary antiphospholipid syndrome with successful pregnancy outcome. Nephrol Dial Transplant; 2005 Aug;20(8):1726-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Steroid-responsive focal segmental glomerulosclerosis in primary antiphospholipid syndrome with successful pregnancy outcome.
  • [MeSH-major] Antiphospholipid Syndrome / drug therapy. Glomerulosclerosis, Focal Segmental / drug therapy. Glucocorticoids / therapeutic use. Nephrotic Syndrome / drug therapy. Pregnancy Complications


9
Advertisement
4. Jovanović M, Bozić M, Kovacević T, Radojcić L, Petronijević M, Vićovac L: Effects of anti-phospholipid antibodies on a human trophoblast cell line (HTR-8/SVneo). Acta Histochem; 2010;112(1):34-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of anti-phospholipid antibodies on a human trophoblast cell line (HTR-8/SVneo).
  • Antibodies to phospholipids (aPL) have been shown to adversely affect trophoblast invasion in vivo and in vitro.
  • Matrigel invasion assay, cytochemistry and cell-based enzyme-linked immunosorbant assay (ELISA) with aPL or normal IgG was used.
  • Our data show that aPL at 100 microg/ml decrease invasiveness of HTR-8/SVneo cells to 60% of control (p<0.01), and this was also shown for primary cytotrophoblast (to 15.5% of control, p<0.001).
  • aPL treatment caused a significant decrease in integrin alpha(1), alpha(5), and beta(1) proteins (86%, 84%, and 87%, respectively).
  • We conclude that HTR-8/SVneo cell culture is a suitable model to study mechanisms of action of aPL on trophoblast, which in HTR-8/SVneo cells inhibit invasion by decreasing integrins alpha(5), alpha(1), and beta(1).
  • [MeSH-major] Antibodies, Antiphospholipid / pharmacology. Trophoblasts / cytology. Trophoblasts / drug effects
  • [MeSH-minor] Antigens, CD29 / metabolism. Cell Line. Cell Survival / drug effects. Female. Humans. Integrin alpha Chains / metabolism. Pregnancy. Pregnancy Trimester, First

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2008 Elsevier GmbH. All rights reserved.
  • (PMID = 18835012.001).
  • [ISSN] 1618-0372
  • [Journal-full-title] Acta histochemica
  • [ISO-abbreviation] Acta Histochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Antiphospholipid; 0 / Antigens, CD29; 0 / Integrin alpha Chains
  •  go-up   go-down


95. Rangachari V, Reed DK, Moore BD, Rosenberry TL: Secondary structure and interfacial aggregation of amyloid-beta(1-40) on sodium dodecyl sulfate micelles. Biochemistry; 2006 Jul 18;45(28):8639-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Alzheimer's disease (AD) is characterized by the presence of large numbers of fibrillar amyloid deposits in the form of senile plaques in the brain.
  • Here we compared the Abeta(1-40) aggregates produced on sodium dodecyl sulfate (SDS) micelles, which may be a better model of biological membranes with phospholipids that have anionic headgroups.
  • At both HFIP and SDS interfaces, changes in peptide secondary structure were observed by CD immediately when Abeta(1-40) was introduced.
  • With HFIP, the change involved an increase in predominant beta-structure content and in fluorescence with thioflavin T, while with SDS, a partial alpha-helical conformation was adopted that gave no fluorescence.
  • [MeSH-major] Amyloid beta-Peptides / chemistry. Micelles. Peptide Fragments / chemistry. Sodium Dodecyl Sulfate / chemistry

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SODIUM LAURYL SULFATE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16834338.001).
  • [ISSN] 0006-2960
  • [Journal-full-title] Biochemistry
  • [ISO-abbreviation] Biochemistry
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amyloid beta-Peptides; 0 / Micelles; 0 / Peptide Fragments; 0 / Propanols; 0 / amyloid beta-protein (1-40); 368GB5141J / Sodium Dodecyl Sulfate; 920-66-1 / hexafluoroisopropanol
  •  go-up   go-down


96. Duman D, Demirtunc R, Duman D, Sungur F, Agirbasli M, Cakmak M: Paradoxical mesentery embolism and silent myocardial infarction in primary antiphospholipid syndrome: a case report. Heart Surg Forum; 2006;9(2):E592-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paradoxical mesentery embolism and silent myocardial infarction in primary antiphospholipid syndrome: a case report.
  • In this case, we describe a 33-year-old man presenting with acute mesenteric ischemia.
  • Coronary angiography revealed complete occlusion of the left anterior descending artery.
  • The diagnosis of primary antiphospholipid syndrome was confirmed by anticardiolipin antibodies test.
  • This is the first reported case presenting with acute paradoxical mesentery embolism accompanying an old myocardial infarction in a young patient with primary antiphospholipid syndrome.
  • [MeSH-major] Antiphospholipid Syndrome / complications. Embolism, Paradoxical / complications. Embolism, Paradoxical / diagnosis. Mesenteric Vascular Occlusion / complications. Mesenteric Vascular Occlusion / diagnosis. Myocardial Infarction / complications. Myocardial Infarction / diagnosis


97. Rückert A, Glimm H, Lübbert M, Grüllich C: Successful treatment of life-threatening Evans syndrome due to antiphospholipid antibody syndrome by rituximab-based regimen: a case with long-term follow-up. Lupus; 2008 Aug;17(8):757-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of life-threatening Evans syndrome due to antiphospholipid antibody syndrome by rituximab-based regimen: a case with long-term follow-up.
  • An association of antiphospholipid antibody syndrome with antibodies directed against either phospholipids or plasma proteins strongly suggest that B-cell dysfunction may be involved in its pathogenesis.
  • Antiphospholipid antibody syndrome with autoimmune cytopenias shows a poor response rate to conventional treatment with anticoagulants, glucocorticosteroids, immunosuppressive agents, intravenous immunoglobulin or plasmapheresis.
  • We report a case of life-threatening antiphospholipid antibody syndrome with Evans syndrome receiving successful multimodal treatment including anti-CD20 monoclonal antibody rituximab with long-term follow-up.
  • [MeSH-major] Anemia, Hemolytic, Autoimmune / drug therapy. Antibodies, Monoclonal / therapeutic use. Antiphospholipid Syndrome / complications. Thrombocytopenia / drug therapy

  • Genetic Alliance. consumer health - Evans Syndrome.
  • Genetic Alliance. consumer health - Antiphospholipid Syndrome.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18625656.001).
  • [ISSN] 0961-2033
  • [Journal-full-title] Lupus
  • [ISO-abbreviation] Lupus
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Immunosuppressive Agents; 4F4X42SYQ6 / Rituximab; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


98. Alijotas-Reig J: [The complement system as a main actor in the pathogenesis of obstetric antiphospholipid syndrome]. Med Clin (Barc); 2010 Jan 23;134(1):30-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The complement system as a main actor in the pathogenesis of obstetric antiphospholipid syndrome].
  • Pregnancy losses are the main obstetrical complications of the obstetric antiphospholipid syndrome (obstetric-APS).
  • Some cases have low plasma C4/C3 levels.
  • The beta2-glycoprotein-I/anti-beta2-glycoprotein-I complexes activate both, classical and alternative complement pathways.
  • In the end, the role played in this binomial by certain pro-inflammatory cytokines, mainly TNF-alpha, remains to clarify.
  • [MeSH-major] Antiphospholipid Syndrome / immunology. Complement System Proteins / physiology. Pregnancy Complications / immunology

  • Genetic Alliance. consumer health - Antiphospholipid Syndrome.
  • MedlinePlus Health Information. consumer health - Health Problems in Pregnancy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier España, S.L. All rights reserved.
  • (PMID = 19656533.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 9007-36-7 / Complement System Proteins
  • [Number-of-references] 38
  •  go-up   go-down


99. Sanmarco M, Bardin N, Camoin L, Beziane A, Dignat-George F, Gamerre M, Porcu G: Antigenic profile, prevalence, and clinical significance of antiphospholipid antibodies in women referred for in vitro fertilization. Ann N Y Acad Sci; 2007 Jun;1108:457-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antigenic profile, prevalence, and clinical significance of antiphospholipid antibodies in women referred for in vitro fertilization.
  • The aim of this prospective study was to assess the prevalence of antiphospholipid antibodies (aPL) in women who had undergone in vitro fertilization (IVF) and the relationship between aPL and IVF outcome.
  • Out of the 101 infertile women, 40 were persistently positive for aPL, showing a prevalence significantly higher than in controls (39.6% versus 5%, P < 0.0001).
  • Among aPL, aPE were found with a significantly higher prevalence compared with LA, aCL, and aP2GPI (67.5% versus 0%, 15%, and 40%, respectively).
  • Interestingly, aPE were found in 70% of the cases in the absence of the other aPL.
  • The predominant isotype of aPL was IgA, in particular for abeta2GPI.
  • Finally, no significant association was found between the presence of aPL and IVF outcome.
  • This prospective study shows aPE as the most prevalent aPL in infertile women and IgA as more common than IgG and IgM.
  • However, our results do not support an association between aPL and IVF outcome.
  • [MeSH-major] Antibodies, Antiphospholipid / blood. Autoantibodies / blood. Fertilization in Vitro. Infertility / blood

  • MedlinePlus Health Information. consumer health - Infertility.
  • Immune Epitope Database and Analysis Resource. gene/protein/disease-specific - Related Immune Epitope Information .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17894010.001).
  • [ISSN] 0077-8923
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Antiphospholipid; 0 / Autoantibodies; 0 / Cardiolipins; 0 / Immunoglobulin A; 0 / Immunoglobulin G; 0 / Immunoglobulin M; 0 / Lupus Coagulation Inhibitor; 0 / Phosphatidylethanolamines; 0 / beta 2-Glycoprotein I; 39382-08-6 / phosphatidylethanolamine
  •  go-up   go-down


100. Ellis R, Boggild M: Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it? Mult Scler; 2009 Apr;15(4):505-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it?
  • BACKGROUND: Therapy-related acute leukaemia (TRAL) is a concern for neurologists and patients when considering treatment with Mitoxantrone for multiple sclerosis (MS).
  • RESULTS: Case-series including 5472 patients were identified; mean dose of Mitoxantrone was 74.2 mg/m(2) (range:12-120 mg/m(2)).
  • Acute Myelocytic Leukaemia and Acute Promyelocytic Leukaemia represented 46.4% each of the leukaemia subtypes.
  • Over 80% of cases occurred in patients exposed to >60 mg/m(2), with a relative risk of 1.44 (CI95%:1.18-1.70) when comparing total dose >60 mg/m(2) against <60 mg/m(2) strongly suggesting a relationship between risk of TRAL and total dose.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Leukemia, Myeloid, Acute / chemically induced. Leukemia, Myeloid, Acute / epidemiology. Mitoxantrone / adverse effects. Multiple Sclerosis / drug therapy. Multiple Sclerosis / epidemiology
  • [MeSH-minor] Acute Disease. Adult. Databases, Factual. Female. Humans. Leukemia, Promyelocytic, Acute / chemically induced. Leukemia, Promyelocytic, Acute / epidemiology. Male. Middle Aged. Risk Factors

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Multiple Sclerosis.
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19251838.001).
  • [ISSN] 1352-4585
  • [Journal-full-title] Multiple sclerosis (Houndmills, Basingstoke, England)
  • [ISO-abbreviation] Mult. Scler.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down






Advertisement